Key result
Continued antiplatelet therapy in hip fracture patients is not linked to increased major bleeding risk.
Why the study?
Perioperative management of antiplatelet medications in hip fracture patients poses a clinical dilemma, balancing thromboembolic risks against potential increased bleeding during and after surgery.
Does continuation of antiplatelet therapy increase perioperative bleeding or prevent thromboembolic events in patients undergoing hip fracture surgery?
Observational (n=104)
Does continuation of antiplatelet therapy increase perioperative bleeding or prevent thromboembolic events in patients undergoing hip fracture surgery?
Routine discontinuation of antiplatelet therapy may not be necessary for patients undergoing hip fracture surgery, as continuation does not significantly increase major bleeding risk.
Answers are grounded in this paper and cite their sources.
Continued antiplatelet use was not associated with increased major bleeding in this cohort; leaves open whether randomized trials should guide perioperative decisions.
Hip fractures in the elderly represent a significant cause of morbidity and mortality. A considerable proportion of these patients are on antiplatelet medications, such as aspirin (Ecospirin) and clopidogrel (Clopitab), for secondary prevention of cardiovascular events. The perioperative management of these medications poses a clinical dilemma, balancing the risk of thromboembolic complications with the potential for increased bleeding during and after surgery. This detailed review critically examines the existing literature regarding the continuation of antiplatelet therapy in patients undergoing hip fracture surgery. Furthermore, we present a retrospective analysis of 104 patients with hip fractures, including 34 patients on antiplatelet therapy (25 on Ecospirin, 7 on Clopitab, and 2 on dual therapy), evaluating the incidence of perioperative bleeding complications and thromboembolic events. Our findings suggest that the continued use of single or dual antiplatelet therapy in this patient population does not significantly increase the risk of major bleeding requiring intervention and may potentially offer protection against thromboembolic events. Therefore, routine discontinuation of these medications may not be necessary and should be individualized based on a careful assessment of the patient's cardiovascular risk and bleeding risk.
No takes yet. Share an insight, caveat, or question.
Mithin Aachi (2025) conducted an observational in Hip fractures (n=104). Antiplatelet therapy vs. No antiplatelet therapy was evaluated on Perioperative bleeding complications and thromboembolic events. Continued use of antiplatelet therapy in 34 of 104 patients with hip fractures did not significantly increase the risk of major bleeding requiring intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: